Genomics Reporting Implementation Guide
3.0.0 - STU3
Genomics Reporting Implementation Guide
3.0.0 - STU3
This page is part of the Genetic Reporting Implementation Guide (v3.0.0: STU3) based on FHIR (HL7® FHIR® Standard) R4. This is the current published version. For a full list of available versions, see the Directory of published versions
Generated Narrative: DiagnosticReport PGxGenomicReportEMERGE
| Subject | Adam B. Everyman Male, DoB: 1951-01-20 ( Medical Record Number: m123 (use: usual, )) |
| When For | 2020-01-01 00:00:00-0500 |
| Reported | 2020-01-01 00:00:00-0500 |
| Performer | Organization some lab |
Report Details
| Code | Value | Flags | Note | When For |
| Therapeutic Implication | Final | 2019-04-01 | ||
| Therapeutic Implication | Final | 2019-04-01 | ||
| Therapeutic Implication | Final | 2019-04-01 | ||
| Therapeutic Implication | Final | 2019-04-01 | ||
| Therapeutic Implication | Final | 2019-04-01 | ||
| Therapeutic Implication | Final | 2019-04-01 | ||
| Genotype display name | CYP2C19*2/*2 | Final | 2019-04-01 | |
| Genotype display name | VKORC1 rs9923231 C/T | Final | 2019-04-01 | |
| Genotype display name | CYP2C9*1/*1 | Final | 2019-04-01 | |
| Genetic variant assessment | Present | Final | 2020-01-01 | |
| Genetic variant assessment | Present | Final | 2019-04-01 | |
| Genetic variant assessment | Present | Final | 2019-04-01 | |
| Genetic variant assessment | Present | Final | 2019-04-01 | |
| Genetic variant assessment | Present | Final | 2019-04-01 | |
| Genetic variant assessment | Present | Final | 2019-04-01 | |
| Genetic variant assessment | Present | Final | 2019-04-01 | |
| Genetic variant assessment | Present | Final | 2019-04-01 | |
| Genetic variant assessment | Present | Final | This variant was confirmed with SANGER sequencing | 2019-04-01 |
| Genetic variant assessment | Present | Final | This variant was confirmed with SANGER sequencing | 2019-04-01 |
| Genetic variant assessment | Present | Final | This variant was confirmed with SANGER sequencing | 2019-04-01 |
Based on the genotype result, this patient is predicted to have a CYP2C19 poor metabolizer phenotype. This genotype information can be used by patients and clinicians as part of the shared decision-making process for several drugs metabolized by CYP2C19 including clopidogrel, voriconazole, amitriptyline, citalopram and escitalopram.
Coded Conclusions:
IG © 2022+ HL7 International / Clinical Genomics. Package hl7.fhir.uv.genomics-reporting#3.0.0 based on FHIR 4.0.1. Generated 2024-12-12
Links: Table of Contents |
QA Report
| Version History |
|
Propose a change